Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

Published:2018-11-12 Issue:12 Volume:24 Page:1859-1866
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Pollyea Daniel A.^ORCID,Stevens Brett M.,Jones Courtney L.,Winters Amanda,Pei Shanshan,Minhajuddin Mohammad,D’Alessandro Angelo,Culp-Hill Rachel,Riemondy Kent A.^ORCID,Gillen Austin E.,Hesselberth Jay R.^ORCID,Abbott Diana,Schatz Derek,Gutman Jonathan A.,Purev Enkhtsetseg,Smith Clayton,Jordan Craig T.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0233-1.pdf

Reference40 articles.

1. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).

2. van Rhenen, A. et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520–6527 (2005).

3. Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).

4. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).

5. Jordan, C. T., Guzman, M. L. & Noble, M. Cancer stem cells. N. Engl. J. Med. 355, 1253–1261 (2006).

Cited by 534 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD+ and substrate binding sites for the treatment of acute myeloid leukemia;European Journal of Medicinal Chemistry;2024-10

2. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia;Leukemia Research;2024-10

3. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

4. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis;Leukemia & Lymphoma;2024-09-05

5. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia;Leukemia Research;2024-09